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of SSRI therapy in PCP settings. Eligible depressed
patients were randomized to treatment (N = 601) and 
naturalistically followed for 9 months. Medication use
was determined by self-report questionnaire. Adequate
treatment was deﬁned as six months continuous medica-
tion. Clinical response was determined by use of the 
SCL-20. Patients were classiﬁed as achieving remission
(score £6), partial response (50% decrease in symptoms),
or non-response. Baseline and end-of-study depression
severity and functioning were compared between groups
deﬁned by response and treatment classiﬁcations. 
RESULTS: Clinical response in this setting was less than
optimal with 45% of adequately treated patients classi-
ﬁed as non-responders. For remitters and partial respon-
ders, the greatest decreases in depression severity were by
the third month. Partial responders had greater depres-
sion severity and lower functioning at baseline and more
severe depression and lower level of functioning than
remitters at the 9-month evaluation. 
CONCLUSIONS: A substantial number of patients were
classiﬁed as non-responders despite adequate treatment
for six months. These patients may be considered under-
treated according to treatment guidelines recommending
dose increases or medication switches for non-responders.
Partial responders are often considered clinically im-
proved in studies, however they were signiﬁcantly more
ill than remitters following treatment.
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ECONOMIC IMPACT OF TREATMENT OF
DEMENTIA FOR GERMANY—A PROGNOSES 
TO 2050
Happich M, Hallauer JF
University Clinic Charite, Berlin, Germany
OBJECTIVE: To assess the development of costs for
dementia in Germany until the year 2050 under different
demographic scenarios and the possible impact of treat-
ment interventions with AChE inhibitors from various
perspectives. 
METHODS: A model to estimate cost differences in
dementia treatment with AChE inhibitors compared to 
a placebo scenario was developed. The model projects 
the number of dementia patients in Germany until 2050
under the assumption of extended life expectancy and
immigration. Markov modeling allows to document the
progression of dementia patients into more severe stages.
Data of the population development were supplied by the
Federal Bureau of Statistics and the German Institute for
Economic Research. Number of patients were calculated
from demographic prognoses considering prevalence of
disease data from a published meta-analyses of the epi-
demiology of dementia. Data about transition probabili-
ties between different disease stages were derived from a
randomized clinical trial of an AChE inhibitor. Disease
stage speciﬁc costs were taken from a cost of illness study
previously published. 
RESULTS: The number of dementia patients will increase
from 1 million to 2.5 million over the next 50 years in
Germany. With treatment there will be 30% less patients
in the most severe, and hence most costly disease stage.
Costs for treatment are offset by cost savings through a
shift of patients to less severe disease stages, if indirect
family and caring costs are included. Reduction of direct
costs due to treatment increase from 0.5 to 1.5 billion
Euro per year and indirect cost reductions are 4-fold these
ﬁgures. For 2000 net savings of 1.4 billion Euro are
demonstrated for the societal perspective. Results are
stable for extensive sensitivity analysis. 
CONCLUSION: Results document that the dimension 
of cost for care should make dementia a health policy 
priority. In an ageing society dementia treatment is also
economically highly attractive.
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OBJECTIVE: To examine the extent to which length 
of observation affects appropriate identiﬁcation of 
concomitant diagnoses. 
METHODS: Study was conducted using IMS HEALTH’s
LifeLinkTM database, a U.S. employer claims database
consisting of more than 1.8 million covered lives, with
linked medical and pharmacy claims for employees,
dependents, and retirees from 1991 forward. All patients
who had at least one claim for Type II diabetes between
April 1, 2000 and September 30, 2000 were selected.
Additionally, patients were required to be continuously
eligible for the entire 36 months preceding their diagno-
sis to ensure complete data. All diagnoses recorded on
medical claims in 6, 12, 24, and 36-month periods pre-
ceding the diabetes diagnosis were summarized at the 3-
digit ICD-9-CM level. Each time period was cumulative,
such that, patients in the 6-month period also were
observed in the 12-, 24- and 36-month periods, and the
number of patients identiﬁed with a comorbid condition
accumulated across the periods. 
RESULTS: 43,640 patients met the inclusion criteria. 
In comparing the percent of patients with comorbid 
conditions in a six-month observation period versus a 36-
month observation period, the percent of patients with
comorbid conditions increased dramatically. Large 
percentage increases between the 6-month to 36-month
observation periods were found for numerous chronic
comorbidities. For example, the percentage of type II 
diabetics with transient cerebral ischemia increased from
1.9% to 6.5% (243% increase). Other increases included:
depressive disorder (228%), angina (227%), hypertensive
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heart disease (207%), myocardial infarction (204%),
asthma (186%), peripheral vascular disease (184%),
stroke (144%), chronic ischemic heart disease (96%), and
essential hypertension (74%). 
CONCLUSIONS: The percent of patients with comorbid
conditions increases as the observation window increases.
Restricting a search of concomitant diagnoses to a short
timeframe or timeframes of non-continuous enrollment
can result in inaccurate identiﬁcation of chronic comor-
bid conditions of a study population.
DB2
QOL INDICATORS OF SATISFACTION AND
IMPACT ASSOCIATED WITH WEB-ENABLED
DIABETES SELF-MANAGEMENT TOOLS
Atherton M1, Becker MA2
1George Mason University, Fairfax,VA, USA; 2PDHI, INC,
Bernardsville, NJ, USA
According to the California Healthcare Foundation, 40
percent of Americans will suffer from a chronic disease
by 2010. To reach and positively impact this growing
segment of healthcare consumers, many health plans have
initiated some form of disease management. In attempt-
ing to deliver the most effective and targeted intervention
possible, many plans are turning to the Internet and
online tools for patient-directed self-management. 
OBJECTIVES: The purpose of this research is to 
evaluate the efﬁcacy and patient outcomes associated
with an online disease self-management tool for diabet-
ics. 
METHODS: During 1999–2001, 15,600 unique individ-
uals registered as participants in MyDiabetes.com, 
completing two or more visits. Of these, 160 participants
completed a baseline and follow-up DQOL survey online.
Using the median number of visits (median = 25 visits)
during their participation, this group was then equally
divided into low and high volume visitors to the website.
DQOL scale scores are based on a scale of 100 units
derived from instrument question responses. 
RESULTS: Among the high volume users (more than 25
visits), we found evidence of improvement over baseline
in DQOL scale indicators for satisfaction (Bonferroni
pairwise ttest = 3.7, p < 0.001) and impact (Bonferroni
pairwise ttest = 1.7, p < 0.09). Because this group of par-
ticipants was not randomly assigned to this intervention,
some caution is advised in interpreting these results. It
may be that healthier and more health-conscious patients
with diabetes choose to engage in disease management
programs and report improvement based on subjective
factors. However, among those patients with diabetes
who choose to register and participate in web-enabled
disease self-management programming, this evaluation
provides preliminary evidence of self-reported improve-
ment in patients’ satisfaction and perceived disease
impact associated with an Internet-based program. 
CONCLUSIONS: Web-enable disease self-management
programming for patients with diabetes may therefore be
an effective model for health plans eager to engage their
“at risk” members in patient-directed care. Given the 
magnitude of chronic disease prevalence in the US, more
study of the impact and efﬁcacy associated with these
‘new technology’ interventions is needed.
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DIABETIC FOOT ULCERS:THE ECONOMIC
CONSEQUENCES OF INPATIENT ADMISSIONS
OVER FIVE YEARS
O’Brien J, Patrick A, Caro JJ
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OBJECTIVE: Diabetic foot ulcers (DFU) are a common
and costly problem for patients with diabetes. This 
study was undertaken to identify patients with DFU who
required inpatient management in 1995 and their 
readmissions for this problem over a ﬁve-year period, as
well as the resulting costs. 
METHODS: The index DFU admission was identiﬁed 
in the 1995 Massachusetts (MA) inpatient database by
means of primary and secondary ICD-9 diagnosis codes,
excluding cases with any type of lower extremity ampu-
tation or arterial graft. Readmissions for DFU care with
and without lower leg osteomyelitis were tracked over
ﬁve years (1995–1999) by means of a unique patient 
identiﬁer. MA costs, adjusted to national values, were
derived from the all payer state discharge databases. All
accommodations, ancillaries and physician care were
included in the cost estimates, which were adjusted for
medical inﬂation, cost-to-charge ratios, and reported in
2000 US$. 
RESULTS: Males comprised 59% of the index group of
542 patients. The mean age was 65 years (range: 23–99
years) and 1.3% died during the index admission. Of the
survivors, 53% were readmitted at least once (mean 2.1,
range: 1–18) within ﬁve years for DFU management with
or without osteomyelitis for a total of 9,143 inpatient
days, including the index admission. The cumulative 
ﬁve-year cost for the index admission and all readmis-
sions was estimated at $8.5 million. 
CONCLUSIONS: A substantial number of patients with
DFU requiring inpatient management can be expected to
incur additional DFU-related hospital costs within ﬁve
years. This is a conservative cost estimate, as post-acute
care costs, such as rehabilitation and home health care
services, were not included. This information supports the
importance of diligent diabetes management in hopes of
preventing or delaying neuropathic complications, such
as DFU, and programs designed to detect and treat DFUs
at an early stage.
